SCHEMBL902606

SCHEMBL902606

CON(C)C(=O)c1nc2ccnn2c(O)c1Cc1ccc(Cl)c(Cl)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A3 Q01959 2/20 0.35
RNASEH1 O60930 1/20 0.35
TSHR P16473 1/20 0.34
PDE4B Q07343 5/20 0.34
PDE4D Q08499 5/20 0.34
PDE4A P27815 4/20 0.34
PDE4C Q08493 4/20 0.34
ALOX15 P16050 1/20 0.34
CRHBP P24387 1/20 0.34
HTT P42858 1/20 0.34
CRHR2 Q13324 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
SLC6A2 P23975 1/20 0.33
SLC6A4 P31645 1/20 0.33
CENPE Q02224 1/20 0.33
CCR2 P41597 1/20 0.33
KDM5A P29375 2/20 0.32
KDM5B Q9UGL1 2/20 0.32
KDM4C Q9H3R0 1/20 0.32
P2RX7 Q99572 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL902478 0.87 TSHR (0.39) RNASEH1TSHRPDE4BPDE4DPDE4A
SCHEMBL901506 0.85 RNASEH1 (0.38) RNASEH1TSHRPDE4BPDE4DPDE4A
SCHEMBL902587 0.84 RNASEH1 (0.46) RNASEH1TSHRPDE4BPDE4DPDE4A
SCHEMBL902320 0.84 L3MBTL1 (0.43) PDE4BPDE4DPDE4APDE4CL3MBTL1
SCHEMBL901794 0.83 RNASEH1 (0.37) RNASEH1TSHRPDE4BPDE4DPDE4A
SCHEMBL902329 0.83 PDE4A (0.47) RNASEH1TSHRPDE4AALOX15CRHBP
SCHEMBL902327 0.82 PYGL (0.35) SLC6A3RNASEH1TSHRPDE4BPDE4D
SCHEMBL15274725 0.78 HTT (0.37) RNASEH1TSHRALOX15CRHBPHTT
SCHEMBL902398 0.78 PRKAB2 (0.34) TSHRALOX15CRHBPHTTCRHR2
SCHEMBL15274730 0.78 PDE4D (0.46) PDE4BPDE4DPDE4APDE4CL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130252951-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS PROXIMAGEN LIMITED (GB) 2013-09-26 US disclosed
US-20130252951-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS PROXIMAGEN LIMITED (GB) 2013-09-26 US disclosed
US-20130252951-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS PROXIMAGEN LIMITED (GB) 2013-09-26 US disclosed
EP-2621928-A1 7-HYDROXY-PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS Proximagen Limited (GB) 2013-08-07 EP disclosed
WO-2012041817-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS PROXIMAGEN LTD (GB) 2012-04-05 WO disclosed
WO-2012041817-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS PROXIMAGEN LTD (GB) 2012-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130252951-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS CCR2, CCR5, CCR1 SLC6A3 3051/4885RNASEH1 1804/4885TSHR 531/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.